160
Participants
Start Date
January 31, 2011
Primary Completion Date
January 31, 2013
Study Completion Date
January 31, 2013
Enbrel
25mg biweekly or 50mg per week, subcutaneous injection
No. 199, Haerbin
Shanghai Changning Guanghua Integrative Medicine Hospital, Beijing
Shanghai Jiaotong University Affiliated Third People's Hospital, Shanghai
Jiangsu Province Hospital/Department of Rheumatology, Nanjing
Affiliated Hospital of Nantong University, Nantong
Fujian Provincial Hospital, Fuzhou
Daping Hospital, Chongqing
The Second Xiangya Hospital of Central South University, Changsha
The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou
Si Chuan Huaxi Hospital/Rheumatology Department, Chengdu
Lanzhou University Second Hospital, Lanzhou
Xinjiang Uygur Autonomous Region People's Hospital, Ürümqi
The First Affiliated Hospital of Baotou Medical College, Baotou
The Second Hospital of Shanxi Medical University, Taiyuan
Baotou Central Hospital, Baotou
Lead Sponsor
Pfizer
INDUSTRY